SHERMAN JEFFREY W — SEC Form 4 filings
SEC reporting owner CIK 1230482. 8 Form 4 filings on record with FilingPulse; latest filed 2026-05-20.
Transaction summary — filings shown
Covers all 8 filings on record, filed 2024-04-11 to 2026-05-20. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 5,000 shares, $25,000 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 42,232 shares, $334,515 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 8.
- Largest priced transaction: sale of 42,232 shares @ $7.92 ($334,515) in Xeris Biopharma Holdings, Inc., filed 2025-08-29.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | Director | 4 | — | 1 leg · 42,232 sh · $334,515 | 5 |
| Larimar Therapeutics, Inc. (LRMR) | Director | 4 | 1 leg · 5,000 sh · $25,000 | — | 3 |
Form 4 filings — SHERMAN JEFFREY W
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-20 | 4 | Larimar Therapeutics, Inc. (LRMR) | Grant/award (A): 55,150 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Larimar Therapeutics, Inc. (LRMR) | Purchase (P): 5,000 @ $5 | EDGAR |
| 2025-08-29 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Option exercise (M): 47,040 @ $6.66 · Sale (S): 42,232 @ $7.92 · Option exercise (M): 47,040 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Grant/award (A): 50,000 @ $0 | EDGAR |
| 2025-05-14 | 4 | Larimar Therapeutics, Inc. (LRMR) | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2024-06-05 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Grant/award (A): 50,000 @ $0 | EDGAR |
| 2024-05-31 | 4 | Larimar Therapeutics, Inc. (LRMR) | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2024-04-11 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Other (J): 6,502 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1230482 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →